Cinarizine - instructions for use, dose, side effects, contraindications

It blocks calcium channels of L and T type. Inhibits the entry of calcium ions into cells and reduces their content in the depot. Reduces the tone of smooth muscle elements of the arterioles, improves coronary and peripheral blood circulation. Has a high tropism to the vessels of the brain, improves cerebral circulation, reduces headache, tinnitus.Suppresses reactions to biogenic vasoconstrictors (adrenaline, norepinephrine, bradykinin). Increases the elasticity of erythrocyte membranes and lowers the viscosity of the blood. Increases the resistance of cells to hypoxia. Reduces the excitability of the vestibular apparatus, including suppresses nystagmus. Has moderate antihistaminic activity. In patients with impaired peripheral circulation improves blood flow to tissues and potentiates postischemic hyperemia.

Pharmacokinetics:

When ingested quickly absorbed. With plasma proteins binds to 91%. Maximum concentrationis determined after 1-3 hours. It is completely metabolized in the liver. 1/3 of metabolites is excreted in urine, 2/3 - with feces. The half-life is4 hours. Does not have teratogenicity.

Indications:

Disorders of cerebral circulation: atherosclerosis of cerebral vessels, ischemic stroke, period after hemorrhagic stroke and craniocerebral trauma, dyscirculatory encephalopathy; dizziness, tinnitus, depression and irritability, rapid mental fatigue, migraine, senile dementia, loss and loss of memory,violation of thinking and inability to concentrate; treatment and prevention of peripheral circulatory disorders (Raynaud's disease, obliterating atherosclerosis, obliterating thromboangiitis (Buerger's disease), diabetic angiopathy, acrocyanosis, intermittent claudication, trophic and varicose ulcers, paresthesia, cold extremities); maintenance therapy for symptoms of labyrinthine disorders, including dizziness, tinnitus (tinnitus), nystagmus, nausea and vomiting; prevention of kinetosis.

ICD-10

XVIII.R40-R46.R45.4 Irritability and anger

XVIII.R40-R46.R42 Dizziness and dizziness

XVIII.R20-R23.R20.2 Paresthesia of the skin

IX.I70-I79.I73.9 Peripheral vascular disease, unspecified

XIX.T66-T78.T75.3 Motion Slicking

IX.I80-I89.I83.0 Varicose veins of the lower extremities with ulcer

IX.I70-I79.I79.2 * Peripheral angiopathy in diseases classified elsewhere

IX.I70-I79.I73.1 Obliterating thromboangitis [Berger's disease]

IX.I70-I79.I73.0 Raynaud's syndrome

IX.I60-I69.I69.3 Consequences of a cerebral infarction

IX.I60-I69.I67.9 Cerebrovascular disease, unspecified

IX.I60-I69.I67.2 Cerebral atherosclerosis

VIII.H80-H83.H81.9 Violation of vestibular function, unspecified

VII.H55-H59.H55 Nystagmus and other involuntary eye movements

VI.G90-G99.G93.4 Encephalopathy, unspecified

VI.G40-G47.G43 Migraine

V.F90-F98.F90.0 Violation of activity and attention

V.F00-F09.F07.2 Postcontasia syndrome

V.F00-F09.F03 Dementia, unspecified

Contraindications:

Hypersensitivity, breast-feeding.

Carefully:

Pregnancy, Parkinson's disease, porphyria, urination disorders, prostate adenoma, epilepsy.

Use with caution in patients with hypertension.

Pregnancy and lactation:

Category of recommendations for FDA is not defined. In pregnancy, the use of cinnarizine is possible only in exceptional cases, when the expected benefit for the mother significantly exceeds the potential risk to the fetus.

For the duration of treatment, breastfeeding should be discontinued.

Dosing and Administration:

Inside, preferably after a meal. Violation of cerebral circulation: 25-50 mg 3 times a day, peripheral circulation disorders: 50-75 mg 3 times a day, imbalance: 25 mg 3 times a day, kinetosis prevention: adults - 25 mg 30 minutes before trips, if necessary, again after 6 hours to the maximum recommended dose of 225 mg. Children are prescribed half the dose for adults.With high sensitivity to cinnarizine, treatment starts with 1/2 dose, increasing it gradually.

Side effects:

From the side nervous system and sense organs: drowsiness, fatigue, headache.

From the side organs of the digestive tract: dry mouth, dyspeptic phenomena, pain in the epigastric region, cholestatic jaundice.

From the side skin integument: increased sweating, manifestations of lupus erythematosus or red flat lichen.

Other: allergic skin reactions, weight gain; very rarely - a tremor of extremities, the raised or increased muscular tone.

Overdose:

Symptoms: vomiting, drowsiness, tremor, excessive lowering of blood pressure, coma.

Treatment: gastric lavage, reception of activated charcoal, symptomatic therapy. There is no specific antidote.

Interaction:

Chemical incompatibility is not known.

With simultaneous use with tricyclic antidepressants, hypnotics, sedatives, ethanol, ethanol-containing drugs, the effect on the central nervous system increases.

With simultaneous use with antihypertensive drugs, hypotensive effect is enhanced; fromnootropic agents, vasodilators - the effect of nootropic and vasodilating agents is enhanced.

Simultaneous reception of phenylpropanolamine reduces the sedative effect of cinnarizine.

Special instructions:

With caution apply during work drivers of vehicles and people whose profession is associated with increased concentration of attention (possible drowsiness, especially at the beginning of treatment).

Patients with Parkinson's disease may be prescribed only if the expected effect of therapy exceeds the risk of worsening of the underlying disease.

With prolonged use, it is recommended to monitor the function of the liver, kidneys and peripheral blood picture.

Instructions

Cinnarizine (Cinnarizinum)